Skip to main content
Premium Trial:

Request an Annual Quote

BGI Dx, Bioscience Genomics Ink NIPT Deal

NEW YORK (GenomeWeb) – BGI Dx, a subsidiary of BGI, and Italian firm Bioscience Genomics today announced they have signed a five-year framework agreement focused on non-invasive prenatal testing.

The agreement defines terms for the collaboration between the parties, as well as activities and exchanges, and specifically facilitates a technology transfer process for Bioscience Genomics' use of BGI's genetic sequencing technology platforms in the NIPT space.

The technology transfer will allow Bioscience Genomics to start offering NIPT services based on BGI's Nifty test. The test will be called the G-Test in Italy.

The cost related to the transfer of the technology, including setting up a laboratory, is €4.56 million ($5.81 million) with a total anticipated investment of €5.76 million.

Bioscience Genomics is a Rome-based spinout of Bioscience Institute in San Marino, Italy and Tor Vergata University in Rome. The firm offers prenatal diagnostics, newborn screening, and blood and cell banking services

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.